Health Care • Biotechnology: Pharmaceutical Preparations
$57.44 ▼ -1.07
(-1.83%)
MKT CAP: $11.33B • VOL: 3.26M
52W L $49 52W H $71
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$48
MEDIAN
$64
MEAN
$65
HIGH
$78
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BMRN TAPE
BMRN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $69.50 | $66.06 | 2025-02-14 | $52.27 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $72.37 | $67.78 | 2025-02-06 | $53.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $65.48 | $63.18 | 2025-01-29 | $55.14 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $58.59 | — | 2025-01-17 | $56.29 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $50.55 | $54.57 | 2025-01-09 | $51.12 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $68.35 | $59.74 | 2024-12-18 | $49.97 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $55.72 | $58.01 | 2024-12-04 | $53.42 | -4.3% | 48% | C |